The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Japan PIII for Atopic Dermatitis Drug Nemolizumab to Begin in October: Maruho
September 8, 2017
- Chugai to Expand Range of Drugs on Its Medication Optimization Support Application
September 8, 2017
- Sumitomo Dainippon Licenses Antiemetic to Maruishi in Japan, US
September 7, 2017
- Eisai, Merck to Expand Enrollment of Keytruda Combination Trials with Lenvima/Halaven
September 6, 2017
- Japanese Drug Majors Ratcheting Up Moves in CAR-T Space
September 6, 2017
- Spera Pharma Begins Business Capitalizing on “Takeda’s” Track Record, Aims to Become Japan’s No. 1 CDMO
September 6, 2017
- Takeda in CAR-T Therapy Pact with NCC/Yamaguchi Univ. Spin-Out
September 5, 2017
- Mitsubishi Tanabe to Beef Up Marketing System in Field of Autoimmune Diseases, Plans to Expand Expert Sales Force
September 5, 2017
- Aspen Completes Takeover of 4 Kyowa Kirin Brands
September 4, 2017
- BIKEN-Mitsubishi Tanabe Vaccine JV Now Up and Running
September 4, 2017
- Seikagaku, Ono Ink Definitive Deal on Osteoarthritis Treatment
September 4, 2017
- Yamaha Enters Medical Field with Cell Handler, a Device to Support Drug Discovery
September 4, 2017
- Mirogabalin Delivers Positive Data for Diabetic Peripheral Neuropathic Pain: Daiichi Sankyo
September 1, 2017
- Daiichi Sankyo Ditches CL-108 Deal, Takes 27.8 Billion Yen Impaired Loss
September 1, 2017
- Daiichi Sankyo Denies Report on AZ’s Acquisition Offer
September 1, 2017
- Opdivo Clinches Batch of New Indications in South Korea
August 31, 2017
- Praluent Self-Injection Possible from Sept. 1; Repatha Auto Mini Doser Approved
August 31, 2017
- Daiichi Sankyo Share Trade Halted after Report on AZ’s Acquisition Offer
August 31, 2017
- Trerief Filed for Parkinsonism in DLB: Sumitomo Dainippon
August 31, 2017
- MSD to Cut 250 Jobs as It Foresees Portfolio Changes
August 31, 2017
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…